The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10109 malaria professionals are enjoying the free benefits of MalariaWorld today

artemisinin combination therapies

NOT Open Access | Viability Screen of LOPAC1280 Reveals Tyrosine Kinase Inhibitor Tyrphostin A9 as a Novel Partner Drug for Artesunate Combinations To Target the Plasmodium falciparum Ring Stage

April 2, 2019 - 11:46 -- NOT Open Access
Author(s): 
Jie Xin Tong, Sarah E. L. Ang, Esther H. N. Tan and Kevin S. W. Tan
Reference: 
Antimicrob Agents Chemother 63:e02389-18

The emergence of artemisinin-resistant Plasmodium falciparum poses a major threat to current frontline artemisinin combination therapies.

Efficacy and Tolerability Outcomes of a Phase II, Randomized, Open-Label, Multicenter Study of a New Water-Dispersible Pediatric Formulation of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in African Infa

December 27, 2017 - 12:49 -- Open Access
Author(s): 
Nicola Gargano, Lola Madrid, Quique Bassat, et al.
Reference: 
Antimicrob. Agents Chemother. January 2018 vol. 62 no. 1 e00596-17

Artemisinin combination therapies are considered the mainstay of malaria treatment, but pediatric-friendly formulations for the treatment of infants are scarce.

NOT Open Access | Indolyl-3-ethanone-α-thioethers: A promising new class of non-toxic antimalarial agents

April 11, 2016 - 16:21 -- NOT Open Access
Author(s): 
Archibald L. Svogie, Michelle Isaacs, Heinrich C. Hoppe, Setshaba D. Khanye, Clinton G.L. Veale
Reference: 
European Journal of Medicinal Chemistry, Volume 114, 23 May 2016, Pages 79–88

The success of chemotherapeutics in easing the burden of malaria is under continuous threat from ever-evolving parasite resistance, including resistance to artemisinin combination therapies.

Development, Evaluation, and Application of an In Silico Model for Antimalarial Drug Treatment and Failure

June 21, 2011 - 06:55 -- Kabogo Ndegwa
Tags: 
Author(s): 
Katherine Winter and Ian M. Hastings
Reference: 
Antimicrobial Agents and Chemotherapy, July 2011,p. 3380-3392, Vol. 55, No. 7

Pharmacological mechanism-based modeling was refined and used to develop an in silico model of antimalarial drug treatment validated against clinical and field data.

Subscribe to RSS - artemisinin combination therapies